FindTrial
Sign In

The effect of using two mouthwashes in the treatment of mucosal inflammation around dental implants

Clinical evaluation of the efficacy of two types of oral antiseptics in the treatment of Mucositis and Peri-Implantitis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-10ch2tf2
Enrollment
Unknown
Registered
2023-09-08
Start date
2020-06-02
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dental Implants

Interventions

This study is a randomized, controlled, triple-blind clinical trial in which 42 systemically healthy volunteers aged between 25 and 65 years will be recruited (21 patients with mucositis and 21 patien
patients will be randomly allocated, by drawing lots, randomly distributed into two groups for mucositis (M1- treatment with chlorhexidine
M2- treatment with blue®m gel), and two groups for peri-implantitis (P1- treatment with chlorhexidine
P2- treatment with blue®m gel). A calibrated examiner (dentist, graduate student in Implantology) will perform a peri-implant evaluation. The depth on probing (PD), modified plaque index (mPI), modifi
D25.583

Sponsors

Universidade Federal de Santa Catarina
Lead Sponsor
Universidade Federal de Santa Catarina
Collaborator

Eligibility

Age
25 Years to 65 Years

Inclusion criteria

Inclusion criteria: Presence of at least 1 titanium dental implant with mucositis or peri-implantitis; presence of sub and supra gingival plaque; signs of inflammation; no maintenance therapy in the last three months; progressive marginal bone loss (MBL) of 3 mm at least one point.Increased probing depth (PD) (6 mm) at least one point; total or partially edentulous patients; residents of the Greater Florianópolis region e greater Florianópolis region.

Exclusion criteria

Exclusion criteria: Carriers of autoimmune diseases; taking anti-inflammatory drugs, antibiotic therapy, or have taken in the last three months; smokers or users of alcohol users; carriers of diabetes mellitus; carriers of neoplasms; carriers of obstructive pulmonary diseases; carriers of renal diseases; renal diseases; patients with familial hypercholesterolemia; patients with other systemic diseases compromise their health of the patient.

Design outcomes

Primary

MeasureTime frame
To verify the effect of the two methods in the treatment of peri-implant diseases.—

Secondary

MeasureTime frame
No secondary outcomes are expected.—

Countries

Brazil

Contacts

Public ContactThalles Balduino

Universidade Federal de Santa Catarina

thalles.balduino@posgrad.ufsc.br+554837219077

Outcome results

None listed

Source: REBEC (via WHO ICTRP)